Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
Background Immune checkpoint blockers (ICBs) have been approved by the Food and end table Drug Administration to be used alone in front-line therapies or in combination with other regimens for certain advanced cancers.Since ICB only works in a subset of patients and has limited efficacy in treating ovarian cancer (OVC), developing preclinical model